Sector News

Jamere Jackson elected to Lilly Board of Directors

August 31, 2016
Life sciences

The board of directors of Eli Lilly and Company has elected Jamere Jackson as a new member, effective October 1, 2016. As a member of Lilly’s board, he will serve on the Audit and Finance committees.

Jackson is currently chief financial officer of Nielsen Holdings plc (Nielsen).

“I am delighted to welcome Jamere Jackson to the Lilly board,” said John C. Lechleiter, Ph.D., chairman, president and chief executive officer. “Jamere brings a wealth of global financial experience, including a strong background in strategic planning. His experience at Nielsen will also provide an important perspective to our business and help broaden our understanding of consumer markets and strategies.”

Prior to joining Nielsen in 2014, Jackson was with General Electric (GE). His last position there was vice president and chief financial officer for GE Oil & Gas, drilling and surface division. In that role, he was responsible for driving financial rigor, developing strategy and implementing change across the drilling and surface portfolio.

Jackson joined GE in 2004 as the chief financial officer for Global Business Services. He then became chief financial analyst for GE Corporate before being promoted to chief financial officer for GE Aviation Military Systems. Next, he was named chief financial officer for GE Aviation Systems, where he led a global team focused on expanding GE’s jet-engine business beyond its core products.

Jackson’s experience also includes positions at First Data Corporation, Total System Services, Pizza Hut Inc., and Procter & Gamble Company. He is a certified public accountant and received his undergraduate degree in finance and business economics from the University of Notre Dame.

Source: Eli Lilly and Company

comments closed

Related News

May 26, 2024

From pharma to food: Vitafoods 2024 highlights

Life sciences

Beyond the vibrant displays and insightful discussions at Vitafoods 2024 stood the backdrop of a rapidly expanding nutraceutical market. With consumers increasingly seeking preventive healthcare solutions and natural alternatives to traditional medicine, the global nutraceutical industry has witnessed remarkable growth in recent years.

May 26, 2024

Genmab completes acquisition of ProfoundBio

Life sciences

Genmab has completed its $1.8 billion acquisition of ProfoundBio, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers.

May 26, 2024

Merck to acquire life science company Mirus Bio

Life sciences

Merck has agreed to acquire US life sciences company Mirus Bio for $600 million (around €550 million) from Gamma Biosciences, a life sciences platform established by global investment firm KKR. Based in Madison, Wisconsin, Mirus Bio is a specialist in the development and commercialization of transfection reagents.

How can we help you?

We're easy to reach